Diabetic Angiopathies Completed Phase 1 / 2 Trials for Ranibizumab (DB01270)

IndicationStatusPhase
DBCOND0031847 (Diabetic Angiopathies)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01746563Intravitreal Ranibizumab Combined With Panretinal Photocoagulation in Patients With Proliferative Diabetic RetinopathyTreatment